Ferric citrate - PUMC Pharmaceutical

Drug Profile

Ferric citrate - PUMC Pharmaceutical

Alternative Names: FC 818

Latest Information Update: 06 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PUMC Pharmaceutical Company
  • Class Antianaemics; Ferric compounds; Hyperphosphataemia therapies; Small molecules; Tricarboxylic acids
  • Mechanism of Action Phosphate binding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hyperphosphataemia

Most Recent Events

  • 06 Jan 2016 Phase-II clinical trials in Hyperphosphataemia in China (unspecified route) before January 2016
  • 06 Jan 2016 PUMC Pharmaceutical plans a phase III trial for Hyperphosphataemia in China (PUMC Pharmaceutical pipeline)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top